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 Abstract.  Reports on treatment failures associated with the use of first- and second-line antimalarial drugs chloro-
quine and sulfadoxine-pyrimethamine have recently increased in many parts of Indonesia. The present study evaluated 
artemisinin-based combination therapy for treatment of persons with uncomplicated  Plasmodium falciparum malaria in 
West Sumba District, East Nusa Tenggara Province. A total of 103 persons 1–57 years of age were enrolled, given stan-
dard artesunate-amodiaquine therapy, and followed-up for 28 days. All persons clinically recovered, but two persons were 
again parasitemic on day 7. This finding indicated that these two persons had recurrent parasitemias on days 21 and 28. 
Molecular analyses suggested both recurrences were caused by reinfections. There were no severe adverse events, but 
complaints of gastrointestinal upset, nausea and vomiting, and headache linked to therapy occurred among 9.7%, 5.8% 
and 5.8% of the persons, respectively. Artesunate-amodiaquine proved efficacious therapy for treatment of persons with 
uncomplicated  P. falciparum malaria at one site in eastern Indonesia but it may have tolerability problems that merit fur-
ther investigation. 
 INTRODUCTION 
 The emergence and rapid spread of plasmodia resistant 
to chloroquine (CQ) and sulfadoxine-pyrimethamine (SP) 
within the last few decades has seriously challenged control 
programs in many parts of the world, including Indonesia. 
In 2004, the Ministry of Health of the Republic of Indonesia 
adopted artemisinin-based combination therapy (ACT) into 
its treatment policy. Artemisinin-based combination therapy 
is a combination of artemisinin or related derivative with 
another antimalarial drug such as amodiaquine, piperaquine, 
lumefantrine, doxycycline or SP. The currently licensed and 
available ACTs in Indonesia include artesunate-amodiaquine 
(AS-AQ) and arthemeter-lumefantrin. 1 
 Artemisinin and its derivatives are rapidly absorbed and 
excreted. They achieve therapeutic blood levels within a few 
minutes, parasite clearance within a few hours, and yield a 
reduction in gametocyte carriage time. 2 The partner drug, 
which generally has a longer plasma half-life, serves to elimi-
nate any remaining parasites after the artemisinin has killed 
the parasites. Therefore, successful treatment with an ACT 
may depend upon the response of the parasite to the partner 
drug. In Indonesia, the most commonly used ACT is AS-AQ. 
Amodiaquine is structurally similar to CQ but has been proven 
to be effective against CQ-resistant parasites. 3 However, sev-
eral studies reported certain degrees of cross resistance 
between AQ and CQ. 4,5 Preliminary studies to assess the effi-
cacy of the AS-AQ combination in several sentinel sites in 
Indonesia such as East Sumba, Bangka-Belitung, and South 
Lampung reported relatively high efficacy: 100% at days 14 
and over 90% at day 28. In central Java, the efficacy of ACT 
was 81% at day 28 with late clinical and parasitologic fail-
ures of 7.1% and 11.9%, respectively. Although AQ has never 
been officially used in Indonesia, there is little informa-
tion regarding resistance to this compound in certain areas 6 
(Sutanto I and others, unpublished data). 
 Studies conducted within the past few decades have iden-
tified several molecular markers for the evaluation of drug 
resistance to CQ and SP. These markers have been proven to 
be invaluable tools in assessing the spread of the antimalar-
ial drug resistance in malaria-endemic regions throughout the 
world. 7 
 The present study aimed to evaluate the efficacy of AS-AQ 
combination therapy in the treatment of persons with uncom-
plicated  Plasmodium falciparum malaria. Molecular analyses 
of parasites solved confounding of the efficacy estimate and 
enabled exploration of possible linkage between resistance to 
CQ and AQ. 
 MATERIALS AND METHODS 
 Study site.  The study was conducted in West Sumba District, 
East Nusa Tenggara Province, Indonesia, from May through 
August 2005 and from April through August 2006. The study 
site, West Sumba, is located between 9°18′S and 10°20′S and 
between 108°55′W and 120°23′W. It has an area of 4,051 
km 2 and had a total population of 387,000 persons in 2007. 
The climate is pleasantly cool during the rainy season from 
December to April. The average temperatures are 18–20°C 
during the cooler rainy months from December to April and 
25–33°C during the dry season. The yearly rainfall in West 
Sumba ranges from 1,200 mm to 2,450 mm. Most residents of 
West Sumba are engaged farming. Previous studies reported 
that the malaria prevalence varied substantially from low to 
high endemic with  P. falciparum and  P. vivax predominating. 8 
Entomologic studies conducted in two villages of West Sumba 
District documented 11 species of anopheles in West Sumba 
District:  Anopheles sundaicus ,  An subpictus ,  An barbirostris , 
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 An hyrcanus, An aconitus, An. flavirostris, An. annularis, An. 
maculates, An tesselatus, An. vagus , and  An. kochi (Buwono 
DT, Wahid I, unpublished data). Most of these  Anopheles spe-
cies have been confirmed as malaria vectors in Indonesia. 9 
 In vivo drug efficacy study.  The study was conducted in 
Wanokaka Subdistrict from May through August 2005 and at 
the outpatient clinic of Karitas Hospital from April through 
August 2006. 
 Recruitment of participants.  Participants were recruited 
from malaria-infected persons found during active malari-
ometric surveys or from persons attending outpatient clinics 
at Karitas Hospital. Persons were excluded if they met any of 
the following exclusion criteria: 1) were pregnant, 2) had a his-
tory of allergy to the study drugs or study drug’s derivative, 
3) had previously completed treatment with an antimalarial 
drug in the preceding two weeks, or 4) had a medical history of 
untreated hypertension or chronic heart, kidney, or liver dis-
ease. A total of 103 malaria patients (age range = 1−57 years) 
provided consent to participate in this study. They were exclu-
sively infected with  P. falciparum (parasite density > 500 para-
site/μL), did not show any signs of severe malaria, and had not 
taken any antimalarial drugs in the preceding two weeks. 
 Antimalarial therapy.  All study participants were given a 
supervised treatment of 4 mg/kg of body weight of AS and 
10 mg/kg of body weight of AQ over a three-day period and 
followed-up for 28 days. A study nurse distributed the drugs, 
observed and recorded all treatments, and repeated the treat-
ment if vomiting occurred within 30 minutes of the adminis-
tered dose. Parasitologic responses were classified according 
to criteria of the World Health Organization. 10 Adverse effects 
observed during the study were recorded by the study nurse 
and/or physician. This study was reviewed and approved by 
the Eijkman Institute Research Ethics Commitee for the use 
of human subjects. 
 Laboratory procedures.  At enrollment, a fingerprick was 
performed to obtain blood to prepare thick and thin blood 
smears and blots on filter paper (Whatman International Ltd., 
Maidstone, United Kingdom), for parasite genotyping, and for 
hemoglobin measurements (HemoCue™ Hb201+; HemoCue, 
Angelholm, Sweden). Smears and filter paper blood samples 
were also collected from fingerpricks on days 1, 2, 3, 7, 14, 21, 
and 28. Smears were read by expert microscopists and con-
firmed by polymerase chain reaction (PCR). Any discordant 
results between microscopy and PCR were resolved by inde-
pendent PCR confirmation. 
 Parasitologic analysis.  Thick and thin blood smears were 
stained with Giemsa and subsequently examined by light 
microscopy. Parasite density was determined by counting the 
number of parasites per leukocytes in 100-high-power micro-
scopic fields in a Giemsa-stained thick blood film, assuming 
an average of 20 leukocytes/microscopic field and 8,000 leuko-
cytes/μL of blood. The total number of parasites per microliter 
was multiplied by 40. 11 
 Preparation of genomic DNA.  Parasite and human host 
DNA (on day of enrollment and day of recrudescence) was 
extracted from blood samples using Chelex-100 ion exchanger 
(Bio-Rad Laboratories, Hercules, CA) according to a pre-
viously published procedure. 12 Extracted DNA was either 
used immediately for PCR assays or stored at –20°C for later 
analysis. 
 Genotyping and PCR amplification of  P. falciparum genes. 
 Genotyping using the genes for merozoite surface protein 1 
(MSP1), MSP2, and glutamate-rich protein (GLURP) was 
performed in certain participants to distinguish between 
pre-treatment and recrudescent parasites. Amplifications of 
the  P. falciparum genes for chloroquine resistance trans-
porter (Pfcrt),  P. falciparum multidrug resistance 1 (Pfmdr1), 
dihydrofolate reductase (dhfr), and dihyropteroate synthase 
(dhps) were performed to determine the frequency distri-
bution of the drug-resistant alleles associated with chloro-
quine and SP resistance, according to previously published 
procedures. 13,14 
 RESULTS 
 A total of 103  P. falciparum malaria patients 1–57 years of 
age were included in this study. The demographics of the study 
participants are shown in  Table 1 . At enrollment, the median 
body temperatures was 38.1°C. Hemoglobin levels of the par-
ticipants ranged from 7.3 to 14.7 g/dL and 28.1% had hemo-
globin levels less than 11 g/dL. Of the 103 malaria patients 
treated, 101 had recovered completely by day 7, 1 participant 
retained parasitemia up to day 14, and the remaining 2 par-
ticipants showed reappearance of parasites in blood films on 
days 21 and 28 ( Table 2 ). The presence of gametocytes was 
also observed in 16 participants; this occurred in 6 participants 
on day 7. The most frequent clinical symptoms of participants 
at the time of enrollment were fever, headache, rigors, dizzi-
ness, weakness, nausea, and vomiting ( Table 3 ). 
 Adverse effects.  Nausea, vomiting, and headache also devel-
oped or worsened after initiation of antimalarial therapy in 
9.7%, 5.8% and 5.8% of the participants, respectively. These 
symptoms generally ceased by the end of the course of ther-
apy when AQ is given not simultaneously with AS. No severe 
side effects were noted in any of the participants. 
 Parasite genotypic profiles.  Parasite genotyping of MSP1, 
MSP2, and GLURP genes.  Analysis of parasite genotype on 
day of recrudescence indicated that two participants retained 
parasites on day 7 that had the same genotype of parasites 
found on day 0 but had parasites with different genotypes at 
days 21 and 28 ( Figure 1 ). This result suggests that these par-
ticipants were reinfected with a new strain of  P. falciparum . 
 Polymorphism of pfmdr1 and pfcrt genes.  Molecular analy-
sis of parasites collected throughout the study indicated that 
the 76T allele of the pfcrt gene, a molecular marker for the 
parasite resistance to CQ, was found in 97.1% of the partici-
pants ( Table 4 ). In  pfmdr1 , the proportion of isolates carrying 
the 86Y allele was approximately 20.4% among West Sumba 
isolates. The  pfmdr1 1042D polymorphism was also detected 
in 17 isolates. The two recrudescent parasites were found to 
have the 76T allele of  pfcrt and the 86N allele of  pfmdr1 . The 
proportion of isolates that had the 76T allele of  pfcrt and the 
86Y allele of  pfmdr1 was 17.5%. No polymorphisms at codons 
 T able 1 
 Characteristics of study participants at enrollment 
Characteristic Value
Age, years 29 (1–57)*
Sex, M:F 60:53
Weight, kg 37 (8–66)*
Temperature, °C 38.1 (36.8–39.4)*
Parasitemia/μL 6,300 (600–12,000)*
 *  Median (range). 
916 ASIH AND OTHERS
1032 and 1246 of the  pfmdr 1 gene were observed in any of the 
isolates examined. 
 Polymorphisms in dhfr and dhps genes.  Amplification of the 
dhfr gene indicated that most isolates had the mutant  108N 
allele. The 108T polymorphism was not detected in any of the 
isolates examined. Isolates that had 108N and 59R alleles were 
found in 30.1% of the participants. No polymorphisms were 
observed at codons 16, 50, or 51 in any of the isolates exam-
ined. Amplification of the dhps gene indicated that the 437G 
allele was found in four participants, of which one participant 
had an additional 540E polymorphism. Overall, the proportion 
of participants who had the 108N and 59R alleles of the  dhfr 
gene in combination with the 437G allele of the  dhps gene was 
2.9%. No polymorphisms were observed at codons 436, 581 or 
613 in any of the isolates examined in this study. 
 DISCUSSION 
 As expected, the AS-AQ combination is an effective treat-
ment for persons with uncomplicated  P. falciparum malaria 
in West Sumba District of East Nusa Tenggara Province, 
Indonesia, an area with relatively stable malaria transmis-
sion. 8 Previous studies in several sentinel sites in Indonesia 
have reported variable efficacy of this drug combination 
and reappearance of blood parasites, mostly on days 21 or 
28. Artesunate, the artemisinin derivative used in this com-
bination, has been reported to rapidly clear parasites from 
the blood but because of its very short half-life plasma con-
centrations become undetectable within a few hours after 
administration. 15 The partner drug AQ, particularly its active 
metabolite desethylamodiaquine has a longer half-life of 9–18 
days. 16 Therefore, the AS-AQ combination may provide a sub-
curative concentration of AQ, which may result in reinfection 
with new parasite strains after day 18. 
 In this study, two participants retained parasitemias at day 7 
and after becoming aparasitemic at day 14, parasites reap-
peared in the blood at days 21 and 28, respectively. Analysis of 
parasites genotype at day 7 in both participants indicated that 
both carried the same genotype as that on day 0. However, 
on days 21 and 28, both participants carried different geno-
types. This finding has two implications. First, the presence of 
the parasite at day 7, regardless of whether it carries the same 
genotype of the parasite before treatment or a genotype that 
is different, could be considered as treatment failure by this 
drug combination. Second, reappearance of the parasite with 
 T able 3 
 Clinical and laboratory data of 103 participants at enrollment before 
treatment 
Characteristic No. (%)
Fever 38 (36.9)
Headache 37 (35.9)
Anemia (hemoglobin level < 11 g/dL) 29 (28.1)
Chills 29 (28.1)
Dizziness 25 (24.3)
Weakness 21 (20.4)
Nausea 20 (19.4)
Vomiting 13 (12.6)
Cough 13 (12.6)
Running nose 11 (10.7)
Abdominal pain 8 (7.8)
Epigastric pain 4 (3.9)
Diarrhea 3 (2.9)
Itching 1 (0.9)
 F igure 1.  Polymerase chain reaction products using glutamate-
rich protein oligonucleotides to determine genotype of the parasites 
in two persons who had parasitemias at days 7, 21, and 28, respec-
tively. M =  Ava II – λ DNA marker. Size of the DNA bands for both 
persons are the same on days 0 and 7 but different on days 21 and 28, 
respectively. 
 T able 2 
 Parasite monitoring of participants enrolled in the  in vivo drug 
sensitivity test 
Total enrolled 
at day 0
No. positive after treatment (%)
Day 3 Day 7 Day 14 Day 21 Day 28
103 13 (12.6) 2 (1.9) 1 (0.9) 1 (0.9)* 1 (0.9)*
 *  Indicates different participant. 
 T able 4 
 Genotypic pattern of  Plasmodium falciparum isolates in  dhfr ,  dhps , 
 Pfmdr1 , and  Pfcrt genes* 
Genotypic pattern† Frequency
ACNAKNNT 28
ARNAKNNT 21
ACNAKYNT 14
ACSAKNNT 9
ARNAKNDT 7
ACNAKNDT 3
ACSAAKNNK 3
ARNGKYNT 3
ARNAKYNT 3
ACNAK(N/Y)NT 2
ARNG(K/E)YNT 1
ARNAKNN(K/T) 1
AC(S/N)AKNDT 1
ARNGKNNT 1
ACNGKNDT 1
AR(S/N)AKNDT 1
ACNGKNNT 1
ACSAKYNT 1
ARNAKN(N/D)T 1
AC(S/N)AKNNT 1
 * dhfr = dihydrofolate reductase;  dhps = dihydropteroate synthase;  Pfmdr1 =  P. falciparum 
multiple drug resistance 1;  Pfcrt =  P. falciparum chloroquine resistance transporter. 
 † First letter =  A16V ; second letter =  C59R ; third letter =  S108N/T for the  dhfr gene; 
fourth letter =  A437G for the  dhps gene; fifth letter =  K540E for the  dhps gene; sixth letter =
 N86Y for the  Pfmdr1 gene; seventh letter =  N1042D for the  Pfmdr1 gene; eighth letter = 
 K76T for the  Pfcrt gene. Letters in parenthesis indicate mixed allelic infections. 
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a different genotype at days 21 and 28, respectively strongly 
indicate reinfections, but the possibility that the two partici-
pants carried recrudescent parasites should not be ruled out, 
provided that the PCR fails to detect parasites of minor geno-
types. Nonetheless, whether either recrudescent or reinfection, 
the parasites are likely to be more resistant to AQ than the 
parasite isolates found before the treatment because they sur-
vived a subcurative challenge dose of AQ. 
 In this context, however, it is important to note that the pres-
ence of the 86N allele of  pfmdr1 in both recrudencent parasites 
in addition to the  pfcrt 76T allele is in contrast with a finding in 
Africa where AQ treatment failures are associated with  pfcrt 
76T and  pfmdr1 86Y genotypes. 17–19 Nevertheless, our findings 
support the suggestion that cross-resistance occurred between 
AQ and CQ because  pfcrt 76T and  pfmdr1 single nucleotide 
polymorphisms have been widely regarded as molecular 
markers for CQ resistance. 20 Therefore, our findings indicate 
that AQ resistance might involve another unidentified genetic 
alteration. Overall, treatment of persons with uncomplicated 
malaria with AS-AQ demonstrates the high efficacy of this 
antimalarial drug combination. 
 The persistence of gametocytes in certain participants 
in this study is of particular interest because it implies that 
AS-AQ may not be effective in eliminating gametocytes, thus 
increasing the transmissibility of infection. The ACT combina-
tions have been reported to kill all blood stages of the parasite, 
including gametocytes. 21 Although gametocytes are eventually 
eliminated by day 21, the additional use of primaquine with 
ACT should be considered. 
 In this study, nausea, vomiting, and headache were fre-
quently observed as side effects of drug treatment. These side 
effects were mostly reversible, but they caused patients to be 
reluctant to adhere to therapy. Delayed administration of AQ 
for one hour could reduce these symptoms and alleviate poor 
compliance. This treatment strategy is realistic because AS 
and AQ are usually packaged separately even as combination 
therapy. The use of co-formulation AS-AQ may also increase 
the adherence of the patients because it will reduce signifi-
cantly the amount of the tablets that should be taken daily. 
 Genetic analysis of parasites from infected participants 
indicated that most of the isolates carried the 76T allele of 
the  pfcrt gene. The proportion of the isolates carrying the 86Y 
allele of  pfmdr1 was much lower than that of  P. falciparum 
isolates collected in the other areas of Indonesia. 22,23 However, 
the proportion of isolates carrying the 1042D alleles of  pfmdr1 
in this study was relatively high. The 86Y and 1042D alleles of 
the  pfmdr1 are mutually exclusive and the latter is more fre-
quently found in the eastern part of Indonesia. The 76T allele 
of the  pfcrt gene has been closely linked with CQ resistance, 
whereas the allelic forms of the  pfmdr1 gene have been shown 
to modulate sensitivity to various antimalarial drugs, including 
AS and AQ. 24,25 With regard to reinfection in the two partici-
pants in this study who both carried the 76T allele of  pfcrt and 
the 86N allele of  pfmdr1 , this finding is not in accordance with 
results from Africa, where AQ treatment failures are associated 
with the 76T and 86Y alleles. This discordance indicates that 
AQ resistance may involve other polymorphisms in different 
genes in the parasite. Results from previous investigations of 
the relationship between these genetic alterations in  pfmdr1 
and  in vivo response have often been inconsistent. 2,7,17,26 
 The proportion of isolates carrying mutant alleles of the 
 dhfr and  dhps gene is relatively small in comparison with iso-
lates collected from the other parts of Indonesia. 8,15 In the  dhfr 
gene, only 30% of the isolates carried double mutations, 108N 
and 59R. In the  dhps gene, the proportion of isolates carrying 
the 437G allele, the most commonly found polymorphism, was 
also relatively low in comparison with other areas in Indonesia. 
In this regard, the use of SP as an alternative option to AS-AQ 
could be considered in this area because most  P. falciparum 
isolates are most likely still sensitive to SP. Treatment failure 
associated with SP in Africa is associated with the presence of 
quintuple mutations in  dhfr and  dhps genes, respectively. 27 
 In conclusion, this study indicates that AS-AQ combination 
therapy is highly effective against uncomplicated  P. falciparum 
malaria. The occurrence of treatment failure and reinfection in 
few participants should alert physicians to proper monitoring 
of AS-AQ when used. 
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